Effect of drug metabolizing enzyme gene polymorphism on selective estrogen receptor modulator pharmacokinetics in breast cancer (JBCRG-12)

Effect of drug metabolizing enzyme gene polymorphism on selective estrogen receptor modulator pharmacokinetics in breast cancer (JBCRG-12) - JBCRG-12 (Pharmacokinetics-pharmacogenomics study in breast cancer endocrine treatment)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001665

Enrollment

200

Registered

2009-02-01

Start date

2009-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

Blood test

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Breast cancer patients who are taking either tamoxifen or toremifen

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
CYP2D6 gene polymorphism Pharmacokinetics of tamoxifen and its active metabolites or toremifen and its active metabolites	—

Secondary

Measure	Time frame
Adverse event Drug efficacy	—

Countries

Japan

Contacts

Public ContactHiroshi Ishiguro

Graduate School of Medicine Kyoto University Department of Target Therapy Oncology

hkkishi@kuhp.kyoto-u.ac.jp075-751-4950

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026